Cas No.: | 1080028-80-3 |
SMILES: | C1C2C=C(F)C=C(F)C=2OC[C@@H]1N1C(=S)NC=C1CCNCC1C=CC=CC=1 |
Formula: | C21H21F2N3Os |
M.Wt: | 401.473 |
Purity: | >98% |
Sotrage: | 2 years -20°C Powder, 2 weeks 4°C in DMSO, 6 months -80°C in DMSO |
Description: | Zamicastat is a concentration-dependent dual P-gp and BCRP inhibitor with IC50 values of 73.8±7.2 μM and 17.0±2.7 μM, respectively. |
Target: | IC50: 73.8±7.2 μM (P-gp), 17.0±2.7 μM (BCRP)[1] |
In Vitro: | Zamicastat is a concentration-dependent dual P-glycoprotein (P-gp) and breast cancer resistance protein (BCRP) inhibitor with IC50 values of 73.8±7.2 μM and 17.0±2.7 μM. Zamicastat also reversibly inhibits dopamine β-hydroxylase (DBH) without effect in brain tissue[1]. |
References: | [1]. Bicker J, et al. In vitro assessment of the interactions of dopamine β-hydroxylase inhibitors with human P-glycoprotein and Breast Cancer Resistance Protein. Eur J Pharm Sci. 2018 May 30;117:35-40. |